Research programme: antibody therapeutics - Enumeral Biomedical

Drug Profile

Research programme: antibody therapeutics - Enumeral Biomedical

Alternative Names: 244C8; 388D4; Allosteric anti-PD-1 antibodies - Enumeral; ENUM 244C8; ENUM005; ENUM008; ENUM009

Latest Information Update: 21 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enumeral Biomedical Holdings; University of Texas M. D. Anderson Cancer Center
  • Developer Enumeral Biomedical Holdings
  • Class Antibodies
  • Mechanism of Action CD223 antigen inhibitors; Checkpoint kinase inhibitors; HAVCR2 protein inhibitors; OX40 ligand inhibitors; PDCD 1 protein inhibitors; TIGIT protein inhibitors; VISTA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer
  • Research Inflammation

Most Recent Events

  • 10 Nov 2016 Antibody therapeutics from Enumeral Biomedical are available for licensing as of 10 Nov 2016. www.enumeral.com
  • 15 Jul 2016 Pharmacodynamics and safety data from a preclinical study presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 06 Jun 2016 Pieris Pharmaceuticals in-licenses anti-PD-1 antibody program from Enumeral Biomedical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top